Follow Exelixis to never miss an important update.
A federal appeals court has ruled in favor of Exelixis in its patent fight with MSN Laboratories. The court upheld an earlier decision that protects three patents covering Cabometyx, the company's leading treatment for kidney cancer. This prevents MSN from launching a cheaper generic version of the drug until these specific patents expire.
This is a win for the company because Cabometyx is its primary source of profit. Protecting these patents ensures Exelixis keeps its exclusive right to sell the drug for longer, giving it more time to collect cash and fund its next generation of treatments. While patent battles are common for successful drugs, this ruling removes a major threat to the company's current income.
Source: Business Wire
Truist Financial adjusted its price target to $52 after reviewing the company's recent performance. This is a small change that keeps the target close to where the stock is currently trading. While analysts often tweak these numbers after earnings, this move does not change the overall neutral stance the firm holds on the stock.
Source: Truist Financial
The company earned about 91 cents per share last quarter, beating the 85 cents analysts expected. Total revenue reached nearly 629 million dollars, driven by 573 million dollars from its main kidney cancer drug franchise. While the total sales number was just under the 640 million dollar target, the core business remains highly profitable.
Management is focused on zanzalintinib, its next major drug candidate. Getting this new treatment approved is the key to growing the business as older patents eventually expire. The stock fell about 6 percent today, which looks like a reaction to the slight revenue miss rather than a change in the long-term outlook for its drug pipeline.
See the full quarter, and how our tracked metrics did
Source: 8-K filing
UBS set its target at $55, which is slightly above the current trading price. This suggests the firm sees the stock as fairly valued at these levels. For long-term owners, this is a routine update that aligns with the general analyst view that the company is stable but waiting for its next big drug approval.
Source: UBS
A law firm is investigating whether certain officers and directors put their own interests ahead of shareholders. These types of investigations are common in the biotech industry and often do not lead to serious legal trouble. However, it is worth watching to see if it develops into a formal lawsuit that could distract management or lead to unexpected costs.
Source: Globe News Wire
Management consistently sets targets they can beat, having cleared their own bar for eight straight quarters. This suggests the business is more predictable and disciplined than most of its peers.
| Expectation | |
|---|---|
| EPS | $0.88 |
| Revenue | $647M |